- Home
- CHRS vs ETX Comparison
CHRS vs ETX Comparison
Compare CHRS & ETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ETX
- Stock Information
- Founded
- CHRS 2010
- ETX 2005
- Country
- CHRS United States
- ETX United States
- Employees
- CHRS N/A
- ETX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ETX
- Sector
- CHRS Health Care
- ETX
- Exchange
- CHRS Nasdaq
- ETX NYSE
- Market Cap
- CHRS 84.2M
- ETX 196.3M
- IPO Year
- CHRS 2014
- ETX N/A
- Fundamental
- Price
- CHRS $0.82
- ETX $18.17
- Analyst Decision
- CHRS Buy
- ETX
- Analyst Count
- CHRS 3
- ETX 0
- Target Price
- CHRS $4.68
- ETX N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- ETX 32.7K
- Earning Date
- CHRS 08-07-2025
- ETX 01-01-0001
- Dividend Yield
- CHRS N/A
- ETX 4.20%
- EPS Growth
- CHRS N/A
- ETX N/A
- EPS
- CHRS N/A
- ETX N/A
- Revenue
- CHRS $272,251,000.00
- ETX N/A
- Revenue This Year
- CHRS N/A
- ETX N/A
- Revenue Next Year
- CHRS $106.56
- ETX N/A
- P/E Ratio
- CHRS $1.90
- ETX N/A
- Revenue Growth
- CHRS 19.87
- ETX N/A
- 52 Week Low
- CHRS $0.66
- ETX $16.36
- 52 Week High
- CHRS $2.43
- ETX $18.60
- Technical
- Relative Strength Index (RSI)
- CHRS 53.65
- ETX 52.66
- Support Level
- CHRS $0.72
- ETX $17.97
- Resistance Level
- CHRS $0.77
- ETX $18.30
- Average True Range (ATR)
- CHRS 0.04
- ETX 0.12
- MACD
- CHRS 0.01
- ETX 0.01
- Stochastic Oscillator
- CHRS 91.74
- ETX 60.61
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About ETX EATON VANCE MUNICIPAL INCOME 2028
Eaton Vance Municipal Income 2028 Term Trust is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The fund invests in various sectors such as a bond bank, education, housing, electric utilities, transportation, and others.